SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
SGMO on Nasdaq
Shares outstanding
294,683,714
Price per share
$0.42
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
62,599,661
Total reported value
$42,142,133
% of total 13F portfolios
0%
Share change
-10,625,758
Value change
-$4,085,083
Number of holders
111
Price from insider filings
$0.42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WASATCH ADVISORS LP 2.1% -62% $4,167,240 -$3,664,854 6,188,358 -47% Wasatch Advisors LP 30 Sep 2025

As of 30 Sep 2025, 111 institutional investors reported holding 62,599,661 shares of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO). This represents 21% of the company’s total 294,683,714 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) together control 19% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 3.9% 11,615,150 +24% 0% $7,816,996
RENAISSANCE TECHNOLOGIES LLC 3.5% 10,182,463 +49% 0.01% $6,856,871
BlackRock, Inc. 1.5% 4,556,208 -5.3% 0% $3,068,150
GSA CAPITAL PARTNERS LLP 1.2% 3,662,478 +63% 0.21% $2,466,000
GEODE CAPITAL MANAGEMENT, LLC 1.1% 3,286,476 +41% 0% $2,213,762
TWO SIGMA INVESTMENTS, LP 0.84% 2,479,186 +183% 0% $1,669,484
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.82% 2,420,366 +213% 0% $1,629,874
JANE STREET GROUP, LLC 0.75% 2,200,685 0% $1,481,942
TWO SIGMA ADVISERS, LP 0.72% 2,108,355 +75% 0% $1,419,766
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.52% 1,538,998 +20% 0% $1,036,361
WASATCH ADVISORS LP 0.48% 1,426,453 -82% 0.01% $960,573
STATE STREET CORP 0.46% 1,355,583 +62% 0% $912,850
UBS Group AG 0.45% 1,320,818 +5.7% 0% $888,911
Ikarian Capital, LLC 0.44% 1,294,652 +2.7% 0.2% $871,819
CITADEL ADVISORS LLC 0.41% 1,208,415 +519% 0% $813,747
ORACLE INVESTMENT MANAGEMENT INC 0.34% 1,004,724 0.47% $676,581
JACOBS LEVY EQUITY MANAGEMENT, INC 0.29% 846,533 0% 0% $570,055
Invesco Ltd. 0.27% 808,731 +19% 0% $544,599
HighTower Advisors, LLC 0.25% 744,106 -0.09% 0% $501,081
NORTHERN TRUST CORP 0.22% 639,680 +61% 0% $430,761
MORGAN STANLEY 0.2% 592,153 +3.4% 0% $398,756
ROYAL BANK OF CANADA 0.18% 523,745 +0.66% 0% $352,000
GROUP ONE TRADING LLC 0.17% 502,004 +116% 0.01% $338,049
GOLDMAN SACHS GROUP INC 0.15% 446,854 +145% 0% $300,911
Golden State Equity Partners 0.14% 418,943 +6.9% 0.05% $282,116

Institutional Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 80,133 $34,748 -$209,496 $0.42 3
2025 Q3 62,599,661 $42,142,133 -$4,085,083 $0.67 111
2025 Q2 73,226,420 $39,627,128 -$1,366,580 $0.54 110
2025 Q1 52,557,554 $34,474,526 -$6,973,632 $0.66 118
2024 Q4 61,547,249 $62,817,305 +$5,840,058 $1.02 125
2024 Q3 55,892,914 $48,377,748 -$13,237,737 $0.87 100
2024 Q2 86,880,740 $31,098,958 -$5,513,248 $0.36 126
2024 Q1 100,425,667 $67,257,419 +$9,590,265 $0.67 125
2023 Q4 86,966,421 $47,198,697 -$9,265,269 $0.54 129
2023 Q3 102,314,735 $61,341,591 -$4,250,211 $0.60 131
2023 Q2 105,778,869 $137,125,383 -$10,782,201 $1.30 149
2023 Q1 112,297,853 $197,560,841 +$11,997,591 $1.76 178
2022 Q4 104,011,293 $326,153,436 +$18,050,138 $3.14 179
2022 Q3 97,395,258 $477,415,251 +$38,514,658 $4.90 189
2022 Q2 89,662,495 $371,001,039 +$44,113,066 $4.14 174
2022 Q1 79,972,857 $465,159,583 +$13,325,276 $5.81 184
2021 Q4 76,880,593 $576,854,799 +$14,652,510 $7.50 178
2021 Q3 75,230,827 $678,917,887 -$11,341,782 $9.01 182
2021 Q2 76,183,727 $911,820,230 -$39,619,833 $11.97 189
2021 Q1 79,366,997 $993,813,520 +$8,744,496 $12.53 189
2020 Q4 78,279,519 $1,221,988,081 -$2,887,670 $15.60 215
2020 Q3 81,633,901 $772,262,574 +$39,692,524 $9.45 203
2020 Q2 77,064,448 $690,282,893 +$38,360,714 $8.96 197
2020 Q1 74,003,681 $471,429,640 -$44,160,048 $6.37 175
2019 Q4 78,484,613 $656,787,904 -$35,488,595 $8.37 187
2019 Q3 82,109,589 $743,984,330 +$18,180,888 $9.05 178
2019 Q2 79,874,675 $860,158,811 +$188,076,135 $10.77 178
2019 Q1 65,891,322 $628,583,823 +$8,491,929 $9.54 178
2018 Q4 63,962,974 $734,063,851 -$24,514,588 $11.48 189
2018 Q3 64,628,739 $1,095,486,294 +$6,279,681 $16.95 214
2018 Q2 64,727,770 $919,122,586 +$101,709,560 $14.20 206
2018 Q1 57,191,865 $1,086,683,045 +$32,050,241 $19.00 205
2017 Q4 55,555,574 $911,135,543 +$36,567,117 $16.40 167
2017 Q3 54,652,539 $819,732,570 +$37,421,908 $15.00 147
2017 Q2 53,038,835 $466,764,979 +$100,856,480 $8.80 143
2017 Q1 41,889,756 $217,701,771 +$36,392,442 $5.20 115
2016 Q4 41,299,445 $125,949,665 -$12,015,817 $3.05 120
2016 Q3 43,952,613 $203,488,438 -$12,236,220 $4.63 121
2016 Q2 46,220,859 $267,610,930 -$15,550,987 $5.79 136
2016 Q1 48,689,873 $292,366,107 -$4,019,351 $6.05 142
2015 Q4 49,096,342 $448,268,385 -$26,270,998 $9.13 139
2015 Q3 52,669,346 $297,043,899 -$28,205,503 $5.64 140
2015 Q2 50,554,743 $560,557,135 -$37,822,320 $11.09 156
2015 Q1 52,645,653 $825,232,264 +$55,231,033 $15.68 167
2014 Q4 49,165,950 $747,418,239 +$7,297,640 $15.21 157
2014 Q3 48,823,503 $526,594,567 -$9,059,452 $10.78 157
2014 Q2 48,883,624 $746,320,055 -$18,445,491 $15.27 154
2014 Q1 48,216,512 $871,455,782 +$52,843,003 $18.08 144